论文部分内容阅读
为了客观地评价新的口服头孢菌素CS-807对细菌性肺炎的疗效,安全性和有用性,作者以头孢克罗(CCL)为对照药,采用双盲法进行了研究。剂量原则上为:CS-807,100毫克/次,2次/日;CCL,500毫克/次,3次/日。连续口服14天,结果如下: 1.总投药病例186例,除不能进行评价的42冽(因患者有其他疾病或中途停药等),外对144例(CS-807组75例,CCL组69例)进行了评价。其中细菌性肺炎138例(CS-807组71例,CCL组67例),非细菌性肺炎6例
In order to objectively evaluate the efficacy, safety and usefulness of the new oral cephalosporin CS-807 against bacterial pneumonia, the authors used cefaclor (CCL) as a control drug and studied the double-blind method. The dose is in principle: CS-807, 100 mg / time, 2 times / day; CCL, 500 mg / time, 3 times / day. Continuous oral administration of 14 days, the results are as follows: 1. The total administration of 186 cases, with the exception of 42 冽 can not be evaluated (due to other diseases or discontinuation of patients), external 144 cases (CS-807 group 75 cases, CCL group 69 cases) were evaluated. Among them, 138 cases were bacterial pneumonia (71 in CS-807 group and 67 in CCL group), 6 in non-bacterial pneumonia